Stanozolol 50 - Genetic Pharmaceuticals

Rather than evolving from testosterone, Stanozolol was built from a dihydrotestosterone backbone, modified to avoid estrogenic activity and enhance anabolic function. First released in 1962 as Winstrol by Winthrop Laboratories, it was approved for human use in conditions like cachexia, trauma recovery, and growth disorders. It soon gained veterinary relevance, especially in racehorse treatment. Although it was discontinued in the United States due to regulatory changes, its legal production persists internationally, especially in Europe and Latin America.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Stanozolol 50 by Genetic Pharmaceuticals, consult with your doctor or healthcare professional.